Enhanced Human Growth Hormone Receptor Antagonist Compositions and Methods for Cancer Treatment
Legal Citation
Summary of the Inventive Concept
Improved compositions and methods for treating cancer using human growth hormone receptor antagonists with enhanced efficacy, safety, and pharmacokinetics.
Background and Problem Solved
The original patent disclosed a combination therapy for treating cancer using human growth hormone receptor antagonists. However, the existing patent has limitations in terms of efficacy, safety, and pharmacokinetics. The new inventive concept addresses these limitations by introducing modified antagonists with improved properties.
Detailed Description of the Inventive Concept
The new inventive concept comprises modified human growth hormone receptor antagonists conjugated to polyethylene glycol molecules with branched structures, enhancing their pharmacokinetics and reducing immunogenicity. The antagonists can be formulated with pH-sensitive polymers to improve bioavailability and stability. The compositions can be administered in combination with chemotherapeutic drugs to enhance their efficacy and reduce toxicity. The kit for treating cancer includes a composition with instructions for administration.
Novelty and Inventive Step
The new claims introduce the use of branched polyethylene glycol molecules, pH-sensitive polymers, and modified antagonists with improved pharmacokinetics and reduced immunogenicity, which are not disclosed in the original patent. These modifications provide a significant improvement over the existing technology.
Alternative Embodiments and Variations
Alternative embodiments include using different types of polymers, varying the molecular weight of the polyethylene glycol molecule, and modifying the antagonist to target specific cancer types. Variations of the kit may include different formulations and administration routes.
Potential Commercial Applications and Market
The enhanced human growth hormone receptor antagonist compositions and methods have significant commercial potential in the cancer treatment market, particularly in the areas of breast cancer, central nervous system cancer, melanoma, non-small cell lung cancer, ovarian cancer, prostate cancer, renal cancer, and pancreatic cancer.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K38/27 |
| A | A61 | A61K45/06 |
| A | A61 | A61K47/10 |
| A | A61 | A61P35/00 |
| A | A61 | A61K2039/505 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Biotechnology and pharmaceutical compositions, specifically cancer therapeutics involving growth hormone receptor antagonists, with expertise in protein engineering, drug delivery systems, and molecular modification techniques
Person of Ordinary Skill (PHOSITA) Profile
A researcher with a PhD in molecular biology or pharmaceutical sciences, experienced in protein modification, drug conjugation techniques, polymer chemistry, and cancer treatment strategies, with knowledge of protein-polymer interactions and drug delivery optimization
Obviousness Rationale
A person of ordinary skill would recognize that the PTD's modifications represent predictable variations of the source patent's core technology, involving standard protein engineering and drug delivery techniques that would be apparent to a skilled practitioner seeking to improve growth hormone receptor antagonist compositions for cancer treatment.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,602 |
|---|---|
| Title | Growth hormone antagonist and anti-cancer composition combination therapy |